Goldman Sachs
INO icon

Goldman Sachs’s Inovio Pharmaceuticals INO Stock Holding History

Goldman Sachs’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,683
Closed -$128K – 6495
2017
Q3 		$128K Hold
1,683
– – ﹤0.01% 5964
2017
Q2 		$158K Buy
+1,683
New +$144K ﹤0.01% 5922
2016
Q1 		– Sell
-28,533
Closed -$2.3M – 7186
2015
Q4 		$2.3M Hold
28,533
– – ﹤0.01% 3504
2015
Q3 		$1.98M Buy
+28,533
New +$2.49M ﹤0.01% 3806

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's INO Position: Q1 2026 in Review

Goldman Sachs increased its Inovio Pharmaceuticals (INO) stake by 64% in Q1 2026, buying an estimated $28.7K and bringing the position to 44,724 shares worth $77.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6240.

Goldman Sachs first reported a position in INO in Q4 2013 and has held it in 49 quarters since. The position peaked at $14.4M in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Goldman Sachs held 44,724 shares of Inovio Pharmaceuticals worth $77.8K as of Q1 2026.
  • Goldman Sachs bought 17,436 Inovio Pharmaceuticals shares in Q1 2026, an estimated $28.7K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6240 holding.
  • Goldman Sachs first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
  • Goldman Sachs's Inovio Pharmaceuticals position peaked at $14.4M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.